ewrobbins.com

User Tools

Site Tools

You are here: start » acr2026
acr2026

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
acr2026 [2026/09/21 12:47] – adminacr2026 [2026/09/30 19:52] (current) – admin
Line 1: Line 1:
-**Poster presenter (name, credentials, title, institution)**+====== Admin Details ======
  
-Eric W. Robbins, MD+{{ :itinerary_pwzf4p_28sep_robbins.pdf |itinerary}}
  
-Clinical Fellow+^ place                                    ^ Map ^ Address ^ Phone^ 
 +| Hotel                                | [[ https://maps.app.goo.gl/YD9W4zZMc1fFaBEU9| Hilton Chicago]] | 720 S Michigan Ave, Chicago, IL 60605| 312-922-4400|  
 +| Conference Venue|[[https://maps.app.goo.gl/waGyp1qzgnBwcURt5 | McCormick Place]]|2301 S Martin Luther King Dr, Chicago, IL 60616|312-791-7000|
  
-Critical Care Medicine and Pulmonary Branch; National Heart, Lung, and Blood Institute+^Origin ^ Destination ^ Flight ID^ 
 +| DCA |ORD |AA 1165| 
 +| ORD | DCA| AA 2249|
  
-National Institutes of Health+====== Transit ======
  
-**Poster title:**+App: [[https://www.ventrachicago.com/ | Ventra]]
  
-Serial Quantitative Changes in Anti-Scl-70 Autoantibodies Are Associated with Lung Function Decline in Systemic Sclerosis+<todo>At O'Hare, purchase a 3-day disposable Ventra pass</todo>
  
-**What is your poster about?**+=== From Airport to Hotel ===
  
-Our study investigates whether dynamic, quantitative monitoring of anti-Scl-70 autoantibody titers can predict lung function decline and disease progression in patients with systemic sclerosis (SSc). +CTA Blue line from _O'Hare_ to _Jackson_
-Using a research assay known as luciferase immunoprecipitation systems (LIPS), we evaluated patients from the multicenter CONQUER registry.  +
-We found certain early dynamic changes in quantitative anti-Scl-70 levels were associated with subsequent forced vital capacity (FVC) decline. +
-Specifically, a >30% early increase in anti-Scl-70 levels was associated with a nearly four-fold increased risk of pulmonary progression over two years.+
  
-**Why did you decide to investigate this topic?**+=== From Hotel to Venue ===
  
-Our group had previously done work in myositis-associated interstitial lung disease (ILD), and we wanted to broaden our focus to other rheumatic diseases resulting in pulmonary fibrosis. +  * Option 1: 
-We knew that anti-Scl-70 autoantibodies are a well-established risk factor for SSc–ILD, but we wanted to see if there was a more dynamic measure we could follow that might indicate a patient's risk trajectory. +    * [[https://maps.app.goo.gl/7ToNXXqLJGKFngcN6 | Take bus 3 from directly in front of hotel to venue]] 
-Our hope was to find a measure clinicians could serially monitor to better predict a patient's risk of pulmonary worsening.+  * Option 2: 
 +    * [[https://maps.app.goo.gl/w5rKjyFAurhTronY8 | Walk to Museum Campus / 11th street stop and take Orange line]]
  
-**What are you working on next related to this research?** 
  
-Broadly, we are working on a new project investigating shared proteomic profiles of pulmonary fibrosis across a spectrum of autoimmune rheumatic diseases, such as myositis, SSc, and Sjögren's syndrome.+====== Schedule ======
  
-Simultaneously, to extend the specific work in this abstract, we hope to implement high-breadth proteomic profiling in the CONQUER cohort. +  * Sun, Oct 26 
-We anticipate this expanded analyte coverage will allow us to capture a more comprehensive biological narrative and hopefully uncover molecular signatures tightly correlated with clinical progression. +    * 09:59 flight, DCA to ORD 
- +    * 11:06 arrival in ORD 
-**What excites you most about your work?** +  * Mon, Oct 27 
- +    * 10:30 - 12:30, Marce poster 
-I'm excited about the possibility of having more tools to enable dynamic, proactive monitoring in SSc-ILD care, rather than static risk assessments. +      * Hall F1 
-Identifying an early biomarker trajectory that precedes clinical decline could give rheumatologists and pulmonologists a crucial window of opportunity to tailor their monitoring or therapeutic strategies before irreversible lung damage occurs. +  * Tue, Oct 28 
- +    * 10:30 - 12:30, My abstract 
-**What are you most looking forward to at ACR Convergence 2026 in Orlando?** +      * Hall F1, 1949 
- +    * 17:19 flight, ORD to DCA 
-As a pulmonologist, I look forward to connecting with rheumatology colleagues, translational researchers, and other ILD specialists. +    * 20:16 arrival in DCA
-There's some amazing work going on in the rheumatic biomarker field, and I'm keenly watching several ongoing trials testing new immunotherapies in refractory rheumatologic disease. +
-I am eager to share these insights from the CONQUER cohort, see what other findings presented might be integrated into clinical workflows, and discover new advancements across the field of rheumatology.  +
- +
- +
- +
-  * <del>[[https://rheumatology.org/annual-meeting-abstract-submission | ACR 2026, abstract submission]]</del> +
- +
-=== Registration === +
- +
-Early Registration: August 26, 23:59 EST +
- +
-Timing: November 6–11 +
- +
-=== Abstract Character Limit === +
- +
-  * Title limit: 250 characters, excluding spaces +
-  * Body character limit: 2,750 characters, which EXCLUDES the title, names of authors/co- +
-authors, authors' affiliations, spacing, and disclosures. +
-  * limit of three image, table, and/or graphic uploads per submission. Uploaded tables and/or graphics do not count towards the character limit. +
-  * References in the abstract body will be included in the character count. +
- +
- +
-[[https://www.clinexprheumatol.org/acronyms.asp | acceptable abbreviations]]+
acr2026.1789994847.txt.gz · Last modified: by admin

Page Tools

Except where otherwise noted, content on this wiki is licensed under the following license: CC Attribution-Share Alike 4.0 International
CC Attribution-Share Alike 4.0 International Donate Powered by PHP Valid HTML5 Valid CSS Driven by DokuWiki